Search - tctmd.com

Displaying 81 - 100 of 123

Sort: Relevancy | Date

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

L.A. McKeown

September 13, 2017

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

News Conference News ISET 2016

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Michael O'Riordan

February 10, 2016

News Daily News

Residual Dissection After DCB Treatment for De Novo CAD Generally Resolves

Caitlin E. Cox

November 26, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

News Industry News

The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated Balloon, showing superior efficacy compared to standard PTA

June 25, 2015

News Daily News

EuroPCR 2015 Takes on TAVR, PCI Optimization, and More

Caitlin E. Cox

May 29, 2015

Advertisement

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

TCTMD’s Top 10 Most Popular Stories for December 2018

The Biggest News of 2018: TCTMD’s Top 10

Top News in Endovascular Therapy: 2018

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Drug-Coated Balloon Angioplasty Superior for In-Stent Restenosis of SFA, but Results Leave Much To Be Desired

Residual Dissection After DCB Treatment for De Novo CAD Generally Resolves

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated Balloon, showing superior efficacy compared to standard PTA

EuroPCR 2015 Takes on TAVR, PCI Optimization, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content